Pipeline
Spondyloarthritis is the lead programme
Twelve candidates, four indications, one chemistry. P3T 4.0 is the hit-to-lead candidate; the roadmap shows what has been done and what comes next.
Pipeline · September 2026
SpA first. Then the inflammatory diseases that share its biology.
Twelve candidates across four indications. P3T 4.0 is the hit-to-lead candidate in the spondyloarthritis programme; P3T 7.0 is in discovery and hit-to-lead optimisation for IBD. Spondyloarthritis (SpA) and inflammatory bowel disease (IBD) are deeply interconnected clinical conditions that share overlapping genetic roots, immunological pathobiology and the “gut–joint axis” — which is why the two programmes share one preclinical development path.
* ox-MIF and GPX4 inhibitors are degrader programmes. P3T 4.0 and P3T 7.0 have progressed through hit-to-lead optimisation into preclinical development; the remaining candidates are at target validation.
Hit-to-lead candidate
P3T 4.0 — biology assays
The hit-to-lead candidate from the spondyloarthritis programme has been profiled for absorption, distribution, metabolism and excretion (ADME), predicted human pharmacokinetics, and drug-induced liver injury (DILI) risk against a clinical reference set.
P3T 4.0 — Cell viability at 48 hours
Cell viability (luminescence) after 48 h with LPS + IFNγ stimulation: untreated and stimulated controls, vehicle, two reference drug regimens and four P3T molecules at 100 and 10 µM, three replicates each. P3T 4.0 keeps viability at the level of the stimulated control and the reference drugs at both doses.
Values read from the original figure (±5%); TM-1 = P3T 3.0, TM-2 = P3T 4.0, TM-4 = P3T 5.0, TM-5 = P3T 6.0 per the client. The lab should supply the raw numbers before publication.
P3T 4.0 — ADME and predicted human pharmacokinetics
Compound FKIT-T2_01-2026ADME-ONE runs a full tier-1 ADME panel and a human PK projection on every compound, so liabilities surface early instead of late. Values with ranges are predicted human parameters; experimental inputs are measured.
| Cmin,u (nM) | 24.1 (5.78–72.4) |
| Cavg,u (nM) | 55 (27.5–110) |
| Cmax,u (nM) | 86.1 (55.6–142) |
| Half-life (h) | 4.84 (2.78–8.97) |
| Bioavailability (%) | 72 (62.8–77.7) |
| CLu (mL/min/kg) | 76.5 (41.3–133) |
| Vd,u (L/kg) | 32.1 |
| HLM CLint (µL/min/mg) | 24.5 | Highly favorable |
| MDCK Papp (×10⁻⁶ cm/s) | 4.63 | Moderate |
| MDCK ER | 1.83 | Moderate |
| Solubility (µM) | 80.6 | Moderate / good |
| CYP3A4 IC50 (µM) | >10 | Highly favorable |
| PPB fu | 0.0403 | Challenging |
| LogD | 2.87 |
| pKa | 2 |
ADME-ONE™ — a collaboration between Inductive Bio · Ginkgo Datapoints · Tangible Scientific.
P3T 4.0 — Liver toxicity (DILI)
Lead 1 (P3T 4.0) profiled in primary human hepatocytes against Axiom’s clinical DILI reference set: imaging, transcriptomics and biochemical read-outs.
No evidence of direct cytotoxicity; morphology shifts only at the highest doses tested. Hepatocyte images at 83 µM are similar to DMSO.
P3T 4.0 stays phenotypically quiet versus Axiom’s clinical DILI reference set.
Axiom Translate. Values read from the assay report; the lab should confirm before publication.
Roadmap
From target to launch
The standard path of a new medicine, and where P3T stands on it. Target hypothesis, target-to-hit and hit-to-lead are done; P3T 4.0 is the hit-to-lead candidate now being profiled; lead optimisation and preclinical development, lead-candidate selection and an IND filing are the next milestones.
- Target hypothesis Usually in academiaMay take years or decades · Triple Target Activation concept
- Target-to-hit ~1 yearIdentify promising compounds · in-silico screening
- Hit-to-lead ~1 yearSelect best compound series · 6 TTA molecules synthesised (15 pending), now in in vitro testing
- Hit-to-lead candidate NowP3T 4.0 · ADME, predicted human PK and DILI profiled · P3T 7.0 in discovery for IBD
- Lead optimisation / preclinical ~2 yearsOptimise potency, selectivity and ADME · in vitro and in vivo studies
- Lead candidate · IND ~1 yearLead candidate selection · IND filing (Investigational New Drug)
- Phase I ~1 yearSafety in healthy volunteers
- Phase II ~2.5 yearsEfficacy and safety in patients
- Phase III ~2.5 yearsConfirm effectiveness · monitor adverse effects
- Submission to launch ~1.5 yearsRegulatory review · approval process
Investors
Ready to invest?
P3T is raising a €1M seed round to biological proof of concept. Download the pitch deck or get in touch.